Chart Industries (NYSE:GTLS – Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 12.000-13.000 for the period, compared to the consensus estimate of 12.530. The company issued revenue guidance of $4.7 billion-$4.9 billion, compared to the consensus revenue estimate of $4.9 billion. Chart Industries also updated its FY 2024 guidance to 9.000-9.000 EPS.
Chart Industries Trading Up 8.5 %
GTLS traded up $11.09 during midday trading on Monday, reaching $141.09. 2,065,117 shares of the company were exchanged, compared to its average volume of 630,779. The company has a debt-to-equity ratio of 1.28, a quick ratio of 0.98 and a current ratio of 1.27. The stock has a market capitalization of $6.04 billion, a P/E ratio of 39.68, a PEG ratio of 0.56 and a beta of 1.71. The stock’s 50-day simple moving average is $121.62 and its 200 day simple moving average is $136.98. Chart Industries has a one year low of $101.60 and a one year high of $171.68.
Chart Industries (NYSE:GTLS – Get Free Report) last issued its quarterly earnings results on Friday, November 1st. The industrial products company reported $2.18 earnings per share for the quarter, missing the consensus estimate of $2.56 by ($0.38). Chart Industries had a return on equity of 12.27% and a net margin of 2.80%. The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the prior year, the business earned $1.28 earnings per share. Chart Industries’s revenue was up 18.3% compared to the same quarter last year. As a group, analysts forecast that Chart Industries will post 9.94 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on GTLS
Insider Transactions at Chart Industries
In other Chart Industries news, Director Linda S. Harty bought 5,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was purchased at an average cost of $48.05 per share, with a total value of $240,250.00. Following the transaction, the director now directly owns 5,000 shares in the company, valued at $240,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Jillian C. Evanko purchased 440 shares of Chart Industries stock in a transaction dated Thursday, September 5th. The stock was bought at an average cost of $114.31 per share, for a total transaction of $50,296.40. Following the completion of the transaction, the chief executive officer now owns 125,448 shares in the company, valued at $14,339,960.88. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Linda S. Harty bought 5,000 shares of the stock in a transaction on Monday, September 16th. The stock was purchased at an average price of $48.05 per share, for a total transaction of $240,250.00. Following the completion of the purchase, the director now directly owns 5,000 shares in the company, valued at approximately $240,250. The disclosure for this purchase can be found here. Insiders bought a total of 7,152 shares of company stock worth $482,278 in the last quarter. 0.95% of the stock is currently owned by corporate insiders.
About Chart Industries
Chart Industries, Inc engages in the designing, engineering, and manufacturing of process technologies and equipment for the gas and liquid molecules in the United States and internationally. The company operates in four segments: Cryo Tank Solutions, Heat Transfer Systems, Specialty Products, and Repair, Service & Leasing.
See Also
- Five stocks we like better than Chart Industries
- High Flyers: 3 Natural Gas Stocks for March 2022
- Intel: Is Now the Time to Be Brave?Â
- Best Stocks Under $5.00
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Chart Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chart Industries and related companies with MarketBeat.com's FREE daily email newsletter.